DR-515 Integrative prediction of outcome in metastatic cancers
- Algoritmes
- Behandeling op maat
- Betaaltitel
- Biomarker
- cfDNA
- DNA
- Educatie
- Geen onderdeel van een categorie
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Hergebruik data
- Innovatie
- IT
- Kwaliteit
- Lab proces
- Lerend zorgsysteem
- Medicijn
- Moleculaire diagnostiek
- OncoAct
- oncoanalyser
- OncoAnalyser Dx
- Onderzoek
- Participerende ziekenhuizen
- Pipeline
- Preventie
- Primaire Tumor Onbekend
- Uitbehandeld
- Verhalen patiënten
- Werken in de cloud
- Wetenschappelijke publicaties
- Whole genome sequencing
- Zeldzame kankers
DR-515 Integrative prediction of outcome in metastatic cancers
We are developing multimodal models based on gene expression data and mutational profiles for predicting outcomes in metastatic cancer. From …
DR-545 Multi-modal analysis of metastatic progression and treatment-driven evolution in a pan-cancer whole-genome and transcriptome cohort
Cancers evolve over time. They spread from where they start to other organs, and they adapt when treated, which is …
DR-541 Multi-Cohort Transcriptomic Prediction of Anti-PD-1 Immunotherapy Response and Overall Survival in Skin Cutaneous Melanoma Using Pre-Treatment Bulk RNA-seq
Cutaneous melanoma treated with anti-PD-1 immunotherapy achieves response in only 33–44% of patients, yet no validated pre-treatment biomarker currently guides …
DR-550 Molecular characterisation of adrenocortical tumours for improved disease modelling and precision treatment
This project aims to improve understanding and treatment of rare tumours of the adrenal gland, including adrenocortical carcinoma. We are …
DR-543 Pan-Cancer Analysis of Translesion Synthesis and Tobacco-Associated Mutational Processes
Tobacco exposure contributes to cancer in multiple organs and leaves characteristic patterns of DNA mutations. We will analyze somatic genomic …
DR-547 Whole Genome Sequencing of Neuroendocrine Malignancies
Neuroendocrine malignancies encompass a rare form of cancer that can arise throughout the body. Clinical and molecular heterogeneity of neuroendocrine …
DR-531 Validation of a copy-number alteration-based genomic signature for malignant tumour progression and EGFR-targeted therapy response using the Hartwig cancer cohort
Cancer genomes often show large-scale copy-number alterations that may reflect tumour aggressiveness, genomic instability and resistance to therapy. We have …
DR-513 PIP-PREDICT: External validation of biomarkers of immunotherapy response in metastatic melanoma
This project aims to validate predictive biomarker models developed in a clinical trial (NCT06536257) by analysing independent patient data obtained …
DR-540 Integrating genomic and transcriptomic profiles to dissect AR reprogramming and lineage plasticity in metastatic castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) is incurable and highly variable between patients and metastatic sites. We will combine whole-genome sequencing …
DR-537 Variation in the 5S ribosomal RNA gene array and its relationship to TP53 status across metastatic cancers
Every cell builds ribosomes, the machines that make proteins. One small ribosomal component, 5S RNA, is encoded by many near-identical …
DR-525 Prostate RNA sequencing atlas
Prostate cancer progresses from normal tissue to a primary cancer, which then subsequently metastasizes and develops resistance to therapies, most …
DR-529 Validation of a genomic pattern as a predictive biomarker for lack of response to platinum-based chemotherapy
Upfront identification of non-responders to platinum-based chemotherapy will prevent ineffective treatment and drug related toxicity, while facilitating the use of …
De complete DNA-test is een belangrijke stap op weg naar behandeling van vormen van kanker die nu nog niet behandeld kunnen worden met doelgerichte medicijnen.